Table 1 Patient characteristics.
Characteristic N (%)/median [range] | All N = 30 | t(8;21) N = 13 | Inv(16)/t(16;16) N = 17 | P |
|---|---|---|---|---|
Age (years) | 40 [15–68] | 38 [25–68] | 41 [15–60] | 0.950 |
Sex | 1.000 | |||
Male | 18 (60) | 8 (62) | 10 (59) | |
Female | 12 (40) | 5 (38) | 7 (41) | |
AML type | 1.000 | |||
De novo | 29 (97) | 13 (100) | 16 (94) | |
Secondary | 1 (3) | 0 (0) | 1 (6) | |
WBC level(×10^9/L) | 16.87 [1.22–200.02] | 8.00 [2.10–49.52] | 33.76 [1.22–200.02] | 0.054 |
BM blasts(%) | 50 [15–84] | 43 [20–84] | 56 [15–84] | 0.589 |
Additional Cytogenetic abnormalities | 17 (57) | 9 (69) | 8 (47) | 0.283 |
Kinase mutations, No. (%) | ||||
KIT | 16 (53) | 9 (69) | 7 (41) | 0.159 |
FLT3-ITD | 1 (3) | 1 (8) | 0 (0) | 0.433 |
FLT3 D835 | 3 (10) | 2 (15) | 1 (6) | 0.565 |
RAS | 10 (33) | 2 (15) | 8 (47) | 0.119 |
TP53 | 0 | 0 | 0 | |
HMA type | 0.465 | |||
Azacitidine | 18 (60) | 9 (69) | 9 (53) | |
Decitabine | 12 (40) | 4 (31) | 8 (47) | |
